AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.
AXL
hematological cancers
prognostic value
selective inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 Nov 2019
05 Nov 2019
Historique:
received:
18
09
2019
revised:
28
10
2019
accepted:
31
10
2019
entrez:
8
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
AXL belongs to the TAM (TYRO3, AXL, and MERTK) receptor family, a unique subfamily of the receptor tyrosine kinases. Their common ligand is growth arrest-specific protein 6 (GAS6). The GAS6/TAM signaling pathway regulates many important cell processes and plays an essential role in immunity, hemostasis, and erythropoiesis. In cancer, AXL overexpression and activation has been associated with cell proliferation, chemotherapy resistance, tumor angiogenesis, invasion, and metastasis; and has been correlated with a poor prognosis. In hematological malignancies, the expression and function of AXL is highly diverse, not only between the different tumor types but also in the surrounding tumor microenvironment. Most research and clinical evidence has been provided for AXL inhibitors in acute myeloid leukemia. However, recent studies also revealed an important role of AXL in lymphoid leukemia, lymphoma, and multiple myeloma. In this review, we summarize the basic functions of AXL in various cell types and the role of AXL in different hematological cancers, with a focus on AXL in the dormancy of multiple myeloma. In addition, we provide an update on the most promising AXL inhibitors currently in preclinical/clinical evaluation and discuss future perspectives in this emerging field.
Identifiants
pubmed: 31694201
pii: cancers11111727
doi: 10.3390/cancers11111727
pmc: PMC6896070
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Leukemia. 2016 Jun;30(6):1431-6
pubmed: 26598018
Mol Cell Biol. 1993 Aug;13(8):4976-85
pubmed: 8336730
Clin Cancer Res. 2017 Jun 1;23(11):2842-2855
pubmed: 27852702
J Biol Chem. 2018 Oct 5;293(40):15397-15418
pubmed: 30108175
Nat Biotechnol. 2013 Sep;31(9):775-6
pubmed: 24022140
Cancer Res. 2019 May 15;79(10):2634-2648
pubmed: 30914429
Protoplasma. 2017 Mar;254(2):1091-1101
pubmed: 27549806
Clin Exp Metastasis. 2003;20(7):665-74
pubmed: 14669798
Oncotarget. 2014 Oct 15;5(19):8818-52
pubmed: 25344858
Cancer Res. 2014 Sep 15;74(18):5152-64
pubmed: 25136066
Blood. 2011 Feb 10;117(6):1928-37
pubmed: 21135257
Cancer Lett. 2008 Sep 18;268(2):314-24
pubmed: 18502572
J Pathol. 2015 Sep;237(1):14-24
pubmed: 25965880
Invest New Drugs. 2013 Aug;31(4):833-44
pubmed: 23275061
Mol Cancer Res. 2019 Feb;17(2):356-369
pubmed: 30291220
Cancer Lett. 2016 Jul 1;376(2):218-25
pubmed: 27060207
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5799-804
pubmed: 16585512
Theranostics. 2016 May 24;6(8):1205-19
pubmed: 27279912
Autophagy. 2016 Dec;12(12):2326-2343
pubmed: 27780404
Drugs. 2019 Feb;79(3):331-339
pubmed: 30721452
Nat Commun. 2019 Jan 16;10(1):259
pubmed: 30651547
Leukemia. 2015 Mar;29(3):696-704
pubmed: 25102945
Sci Rep. 2016 Nov 07;6:36520
pubmed: 27819283
Blood. 2013 Oct 3;122(14):2443-52
pubmed: 23982172
J Biol Chem. 1995 Mar 17;270(11):5702-5
pubmed: 7890695
Cancer Res. 2010 Feb 15;70(4):1544-54
pubmed: 20145120
Mucosal Immunol. 2015 Sep;8(5):1021-1030
pubmed: 25603826
Oncogene. 2013 Feb 7;32(6):689-98
pubmed: 22410775
Eur J Immunol. 2018 May;48(5):855-860
pubmed: 29400409
Blood. 2009 Mar 12;113(11):2470-7
pubmed: 18840707
Oral Oncol. 2015 Jul;51(7):683-9
pubmed: 25910588
Nat Immunol. 2006 Jul;7(7):747-54
pubmed: 16751775
J Clin Oncol. 2013 Oct 10;31(29):3639-46
pubmed: 24002501
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Blood. 2016 Dec 8;128(23):2599-2606
pubmed: 27737890
Clin Cancer Res. 2017 May 1;23(9):2289-2300
pubmed: 27856601
Biochimie. 2018 Nov;154:127-131
pubmed: 30176265
Oncotarget. 2015 Sep 15;6(27):23281-96
pubmed: 25966280
Oncogene. 1996 Feb 1;12(3):471-80
pubmed: 8637702
Blood. 2016 Jul 21;128(3):410-4
pubmed: 27307295
Int J Mol Sci. 2019 Jul 02;20(13):null
pubmed: 31269715
Mol Cell Biol. 1991 Oct;11(10):5016-31
pubmed: 1656220
EMBO J. 2006 Jan 11;25(1):80-7
pubmed: 16362042
Nat Chem Biol. 2014 Nov;10(11):977-83
pubmed: 25242553
Cancer Cell. 2015 Apr 13;27(4):533-46
pubmed: 25873175
Mol Carcinog. 2007 Feb;46(2):155-64
pubmed: 17186543
Oncotarget. 2017 Sep 21;8(52):89761-89774
pubmed: 29163786
Oncogene. 1997 Jun 5;14(22):2619-31
pubmed: 9178760
Oncogene. 2019 Jul;38(27):5469-5485
pubmed: 30936462
Blood. 1994 Sep 15;84(6):1931-41
pubmed: 7521695
Neoplasia. 2010 Feb;12(2):116-27
pubmed: 20126470
Oncotarget. 2017 Mar 28;8(13):20645-20655
pubmed: 28423548
J Biol Chem. 2004 Feb 20;279(8):6952-8
pubmed: 14623883
J Biol Chem. 2002 Nov 15;277(46):44164-70
pubmed: 12218057
Cancer. 2018 May 15;124(10):2258
pubmed: 29727493
Cell. 2007 Dec 14;131(6):1124-36
pubmed: 18083102
JCI Insight. 2019 Mar 12;5:
pubmed: 30860495
Blood. 2019 Jul 4;134(1):30-43
pubmed: 31023703
Oncotarget. 2015 Jun 30;6(18):16183-97
pubmed: 25980499
Nat Genet. 2012 Jul 01;44(8):852-60
pubmed: 22751098
Leukemia. 2018 Feb;32(2):252-262
pubmed: 29257139
Mol Cell Biol. 2001 Feb;21(3):902-15
pubmed: 11154277
Blood. 2016 May 12;127(19):2355-6
pubmed: 27020089
Cell. 1995 Feb 24;80(4):661-70
pubmed: 7867073
Blood. 2002 Sep 1;100(5):1532-42
pubmed: 12176867
J Clin Invest. 2017 Jan 3;127(1):183-198
pubmed: 27893463
EMBO J. 2005 Dec 21;24(24):4260-70
pubmed: 16308569
Mol Endocrinol. 2008 Nov;22(11):2481-95
pubmed: 18787040
Mol Cancer. 2019 Feb 11;18(1):24
pubmed: 30744655
J Immunol. 2009 Sep 1;183(5):3004-13
pubmed: 19657094
Life Sci. 2018 Apr 1;198:99-111
pubmed: 29496493
Cancer Res. 2019 Apr 15;79(8):1996-2008
pubmed: 30723115
Haematologica. 2019 Oct;104(10):2017-2027
pubmed: 30923103
Mol Cell Biol. 1997 Aug;17(8):4442-53
pubmed: 9234702
Gastroenterology. 2005 Nov;129(5):1633-42
pubmed: 16285961
Blood. 2013 Mar 14;121(11):2064-73
pubmed: 23321254
Oncotarget. 2018 Dec 14;9(98):37173-37184
pubmed: 30647852
Leukemia. 2014 Jun;28(6):1252-1258
pubmed: 24326683
Clin Cancer Res. 2015 May 1;21(9):2115-26
pubmed: 25673699
J Thromb Haemost. 2010 Aug;8(8):1797-808
pubmed: 20546121
Leukemia. 2014 Feb;28(2):451-5
pubmed: 24217154
Mediators Inflamm. 2017;2017:6848430
pubmed: 28270700
Biochem Biophys Res Commun. 2013 Jun 7;435(3):493-500
pubmed: 23684620
Haematologica. 2009 Mar;94(3):326-34
pubmed: 19211638
Mol Cancer Ther. 2019 Feb;18(2):389-398
pubmed: 30478151
Leukemia. 1999 Sep;13(9):1352-8
pubmed: 10482985
Am J Cancer Res. 2018 Aug 01;8(8):1466-1482
pubmed: 30210917
Exp Hematol. 1997 Nov;25(12):1219-26
pubmed: 9357964
Scand J Immunol. 2019 Aug;90(2):e12777
pubmed: 31075180
Oncogene. 1994 Sep;9(9):2567-78
pubmed: 8058320
Leuk Lymphoma. 2016;57(6):1494-7
pubmed: 26440741
Nat Commun. 2016 Dec 23;7:13898
pubmed: 28008921